CASE Study

Removing Barriers. Expanding Capacity.

How Source BioScience Built a Scalable Digital Pathology Network with HALO AP®

SOURCE BIOSCIENCE AT A GLANCE

Support Over 90 NHS Trusts

280+ Consultant Pathologists

>1 Million Slides Scanned in 2026



UK-Based Laboratories

Nottingham
Head Office | Histopathology

Cambridge
Genomics

Chichester
Histopathology

SOURCE BIOSCIENCE'S DRIVERS FOR CHANGE

- Supporting greater scalability as diagnostic demand and capacity requirements continue to grow.
- Maintaining turnaround times (TATs) while increasing diagnostic capacity.
- Enhancing case management to support efficient coordination of outsourced workflows.
- Supporting NHS cancer pathway targets through streamlined workflows and operational efficiency.
- Creating a digital infrastructure for the future, with the ability to support AI-assisted quality control, clinical trials and advanced image analysis.

THE SOLUTION: HALO AP

Deploy a scalable digital pathology platform designed for high-volume workflows. Enabling Source BioScience to efficiently manage, view, share and analyze digital pathology images at scale. Scanner-agnostic, direct LIMS-to-LIMS integration, faster access to expert pathologists, improved TATs, and fully integrated AI capability and tools for advanced pathology applications.

Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in genomics, multiomics and healthcare diagnostics, partnering with biotechnology, pharmaceutical, healthcare and academia.

HALO AP® is a CE-IVDR marked enterprise diagnostic digital pathology platform that enables anytime, anywhere access to collaborate with colleagues on cases, tumor boards, secondary consultations, clinical trials, as well as quantitative IHC image analysis and AI-driven workflows.

CASE Study

HALO AP by indica labs | Source BioScience

HALO AP® AT A GLANCE

- Designed to scale with increased volumes and evolving requirements
- AI and image analysis capabilities embedded directly in the viewer
- Open APIs for efficient data movement between the IMS and LIMS

SOURCE BIOSCIENCE DIGITAL INTEGRATION PROCESS

DIGITAL



GLASS



2026 digital statistics support same-day TAT.

**Glass average TAT typically falls within 4 days. Contracted to 7 working days.*

A TAILORED APPROACH

Source BioScience offers a flexible, customisable approach to integration across every stage of the digital workflow. They work with hospitals to develop an integration approach that aligns with existing infrastructure, systems and service requirements.

Scanner Integration | **Vendor Integration** | **LIMS-to-LIMS Integration**

THE BENEFITS



CASE Study

HALO AP by indica labs

Source BioScience

INTEGRATION IN PRACTICE

Source BioScience's digital integration model is delivering measurable improvements in real-world clinical workflows. It offers bespoke plugins designed to integrate with existing hospital infrastructure.

LIMS Plugin
Seamless transfer of order messages and issues pathology results and reports into the hospital's LIMS.

IMS Plugin
Seamless access to, and transfer of, digital pathology images through the hospital's IMS.

HALO AP® supports integration by combining an intuitive, pathologist-centric experience with automation and scalability giving Source BioScience the flexibility to build bespoke and more efficient and connected workflows.

THE DIGITAL PROCESS



THE DIGITAL RESULTS

The figures below are drawn from a 2026 case study of 5,721 cases over six months, demonstrating the efficiency of a digitally integrated workflow.

1.8 Days	18%	61%	96%
Average TAT	0-day TAT	≤ 1-day TAT	≤ 5-day TAT

THE IMPACT

Source BioScience's digital integration model enables faster histopathology reporting, helping patients access diagnostic results sooner while supporting hospitals to improve efficiency, increase capacity and meet NHS cancer pathway targets.

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.
TCH-MAR-000019v1